UQ-1-SARS-CoV-2-Sclamp
UQ-1-SARS-CoV-2-Sclamp Uses, Dosage, Side Effects, Food Interaction and all others data.
The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, UQ-1-SARS-CoV-2-Sclamp. The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in combination with a well-established adjuvant technology, MF59, from Seqirus. The UQ-1-SARS-CoV-2-Sclamp Vaccine was developed within 3 weeks and moved immediately into preclinical testing through partnership with Dutch company, Viroclinics Xplore. Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and induced a strong T-cell response. As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932). TetraQ, Australian National University (ANU), the University of Melbourne, and the Peter Doherty Institute for Infection and Immunity are also involved in the clinical component.
| Trade Name | UQ-1-SARS-CoV-2-Sclamp |
| Generic | SARS-CoV-2 Sclamp |
| SARS-CoV-2 Sclamp Other Names | SARS-CoV-2 Sclamp adjuvanted vaccine, UQ COVID-19 Vaccine, UQ-1-SARS-CoV-2-Sclamp |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here UQ-1-SARS-CoV-2-Sclamp
